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Abstract: Apurinic/apyrimidinic endonuclease 1 (APE1), the main mammalian AP-endonuclease
for the resolution of DNA damages through the base excision repair (BER) pathway, acts as a
multifunctional protein in different key cellular processes. The signals to ensure temporo-spatial
regulation of APE1 towards a specific function are still a matter of debate. Several studies have
suggested that post-translational modifications (PTMs) act as dynamic molecular mechanisms for
controlling APE1 functionality. Interestingly, the N-terminal region of APE1 is a disordered portion
functioning as an interface for protein binding, as an acceptor site for PTMs and as a target of
proteolytic cleavage. We previously demonstrated a cytoplasmic accumulation of truncated APE1 in
acute myeloid leukemia (AML) cells in association with a mutated form of nucleophosmin having
aberrant cytoplasmic localization (NPM1c+). Here, we mapped the proteolytic sites of APE1 in AML
cells at Lys31 and Lys32 and showed that substitution of Lys27, 31, 32 and 35 with alanine impairs
proteolysis. We found that the loss of the APE1 N-terminal domain in AML cells is dependent on
the proteasome, but not on granzyme A/K as described previously. The present work identified the
proteasome as a contributing machinery involved in APE1 cleavage in AML cells, suggesting that
acetylation can modulate this process.
Keywords: apurinic apyrimidinic endonuclease/redox effector factor 1; cytoplasmic nucleophosmin 1;
proteasome; acute myeloid leukemia; proteolysis
1. Introduction
Apurinic/apyrimidinic endonuclease 1 (APE1) is a multifunctional and essential protein protecting
cells from oxidative and alkylative insults [1], which maintains the genome stability through a DNA
repair action. It is also able to modulate gene expression through redox signaling and transcriptional
activities. Regardless of transcriptional control, modulation of the APE1 interactome under different
conditions and post-translational modifications (PTMs) at specific residues can modify the chemical
Biomolecules 2020, 10, 531; doi:10.3390/biom10040531 www.mdpi.com/journal/biomolecules
Biomolecules 2020, 10, 531 2 of 14
characteristics and the structural conformation of the protein, redirecting APE1 toward a specific
function. The disordered N-terminal region (35 amino acids) plays a key role in: (i) regulating APE1
subcellular localization [2]; (ii) mediating APE1 binding to RNA and to most of the other protein
interactors [3,4]; (iii) controlling the catalytic activity on abasic DNA [5]; (iv) acting as an acceptor of
different PTMs, such as acetylation [5–7], ubiquitination [8,9], and proteolysis [6,10–14]. The proteolytic
cleavage of the N-terminal portion of APE1 is an irreversible modification that has not been well
elucidated in its molecular/functional characteristics. Although the loss of the N-terminus of APE1 does
not alter the enzyme endonuclease activity, it affects its subcellular distribution as a consequence of the
removal of the nuclear localization signal of the protein [5]. The formation of the above-mentioned
truncated protein was reported to be dependent on Granzyme activity [11,12]. Clear evidence has
suggested that the truncated form is not retained within nucleoli but displays a cytoplasmic rather
than a nuclear distribution [11,12]; on the other hand, conflicting data were reported on the effect of
proteolytic cleavage on APE1 endonuclease and redox activities [11].
Recently, we demonstrated that the expression of the NPM1c+ mutant protein in the myeloid cell
line OCI/AML3 and in blasts from acute myeloid leukemia (AML) patients is accompanied by APE1
relocalization to the cytoplasm [13]. Interestingly, we observed an accumulation of truncated APE1
in the cytoplasmic compartment, suggesting that this protein form is destabilized in cells expressing
NPM1c+ protein [13]. The proteolytic site on APE1 in AML cells, as well as the protease responsible
for the generation of its truncated form, are still unknown.
In this study, we performed in vitro proteolysis experiments using different recombinant APE1
protein forms as substrates. The obtained results clearly demonstrated that: (i) the proteolytic events
in AML cells involve the removal of the protein N-terminus, as we previously demonstrated in
other cells [13], and specifically cleavage at Lys31 and Lys32; (ii) proteolysis is not ascribable to a
granzyme-like activity, contrarily to previous investigations [11,12]; (iii) the cleavage of the APE1
N-terminal domain in AML cells depends on the proteasome complex activity; (iv) possibly, acetylation
can modulate this process.
2. Materials and Methods
2.1. Cell Culture and Materials
OCI/AML2 and 3 cells were grown in alpha-MEM (Euroclone, Milan, Italy) supplemented with
20% fetal bovine serum, 100 U/mL penicillin and 10 µg/mL streptomycin sulfate. Jurkat and HL-60
cells were grown in RPMI-1640 medium (Euroclone, Milan, Italy); all cells were supplemented with
10% fetal bovine serum (FBS, EuroClone, Milan, Italy), L-glutamine (2 mM) (Euroclone, Milan, Italy),
penicillin (100 U/mL) and streptomycin (100 mg/mL) (Euroclone, Milan, Italy), and were cultured in a
humidified incubator, at 37 ◦C, in a 5% v/v CO2 atmosphere. All chemical reagents used for treatments
were supplied from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise specified.
2.2. Preparation of the Cell Extracts and Anti-FLAG Co-Immunoprecipitation
Preparation of total cell lysates, cytoplasmic and nuclear extract were performed as previously
described [3]. HeLa cells were transiently transfected with FLAG-tagged APE1 mutants (APE1WT,
APE131-34Ala, APE1K4pleA, APE1N∆33) using the Lipofectamine 2000 Reagent (Invitrogen, Carlsbad,
CA, USA), according to the manufacturer’s instructions, and collected 24 h after transfection.
Co-immunoprecipitation experiments were performed as already described [15].
2.3. In Vitro Proteolysis
Whole, cytoplasmic or nuclear OCI/AML2-3, Jurkat or HL-60 cell lysates were incubated with
FLAG-tagged APE1 mutants in Granzyme cleavage buffer (50 mM Tris-HCl, pH 7.5, 1 mM CaCl2 and 1
mM MgCl2) in a final volume of 20 µL, for the indicated times, at 37 ◦C, as previously reported [11].
Reactions were blocked with 4X Laemmli sample buffer and corresponding products were resolved by
Biomolecules 2020, 10, 531 3 of 14
SDS-PAGE; resulting gels were immunoblotted for FLAG (F1804, Sigma-Aldrich, St. Louis, MO, USA)
or stained with Coomassie R250 (Sigma-Aldrich, St. Louis, MO, USA).
2.4. Western Blotting Analysis
For Western blotting analysis, the indicated amounts of cell extracts were resolved in 12%
SDS-PAGE and transferred onto nitrocellulose membranes (Sigma-Aldrich, St. Louis, MO, USA).
Normalization was performed by using a monoclonal anti-tubulin antibody (T0198, Sigma-Aldrich, St.
Louis, MO, USA), a polyclonal anti-actin (A2066, Sigma-Aldrich, St. Louis, MO, USA) or a monoclonal
anti-FLAG (F1804, Sigma-Aldrich, St. Louis, MO, USA). All the other antibodies used were from
Novus Biologicals (Abingdon, UK). Blot images were acquired and analyzed by using an Odissey CLx
Infrared Imaging system (LI-COR GmbH, Bad Homburg, Germany).
2.5. Peptide Synthesis
A peptide substrate was designed as corresponding to the portion (26-36) present within the APE1
N-terminal region, having a FRET couple at N-[DABCYL, 4-(4-dimethylaminophenylazo) benzoic
acid] and C-[EDANS, 5-(2-aminoethyl) aminonaphthalene-1-sulfonic acid] terminal ends. The peptide
was synthesized and purified as already reported [16]. The peptide identity and purity (>95%) was
ascertained by an LC-ESI-IT-MS analysis that was carried out with a Surveyor HPLC system (Thermo
Fisher Scientific, Waltham, MA, USA) containing a photo diode array (PDA), which was connected
on-line with a LCQ DECA XP mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA)
equipped with an OPTON ion source, operating at 4.2 kV needle voltage and 320 ◦C. Peptide analysis
was carried out with a narrow-bore C18 BioBasic column (50 × 2 mm). The purified peptides were
lyophilized and stored at −20 ◦C until their use. Peptide stock solutions were prepared at 2 mM and
stored frozen until their use.
2.6. Proteolytic Assay
Cell lysate samples (3 µg) were pre-incubated in 50 mM Tris-HCl, pH 7.4, for 5 min at 37 ◦C;
they were added with the above-mentioned peptide substrate, which was present at a concentration
1–100 µM. Final peptide concentration values were estimated through absorbance measurements
of the corresponding DABCYL-group (extinction coefficient at 478 nm: 32000 M−1 × cm−1). After
addition of the lysate at 37 ◦C, peptide enzymatic hydrolysis was measured by recording corresponding
fluorescence emission at 460 nm after excitation at 330 nm for 200 min. All experiments were performed
in 384 low-volume-well plates (well volume 20 µL) with an OPTI PLATETM instrument (PerkinElmer,
Waltham, MA, USA). Experiments were run in triplicate, and corresponding results were reported as
average values ± standard deviation (SD).
To determine the cleavage site(s) in the peptide, a reaction mixture containing 100 µM substrate
solved in the above-described buffer was added with the cell lysate (3 µg), at 37 ◦C for 1 h; the
corresponding reaction products were analyzed by LC-ESI-IT-MS, as reported above.
2.7. RNA Isolation, cDNA Synthesis and PCR
The total RNA from cell lines was extracted with the SV Total RNA isolation System Kit
(Promega, Madison, WI, USA). One microgram of total RNA was reverse transcribed using the iScript
cDNA synthesis Kit (Bio-Rad, Hercules, CA, USA), according to the manufacturer’s instructions. A
semi-quantitative RT-PCR was performed with RedTaq Polymerase (Sigma-Aldrich, St. Louis, MO,
USA). Primers used for the detection of GZMA and GZMB were previously described [17].
2.8. Recombinant Protein
The expression and purification of recombinant proteins from E. coli was performed as previously
described [5,15]. When recombinant proteins were used for in vitro assays, the acronym rAPE1 was
reported in the text.
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2.9. Proteomic Analyses
2.9.1. Purification of Proteases
Cytoplasmic extracts from serum-starved (60 min) OCI/AML3 cells (about 4 mg) were loaded
on a HiTrap SP column (GE Healthcare, Chicago, IL, USA). Then, the resulting flow-through was
directly loaded on a HiTrap Benzamidine column (GE Healthcare, Chicago, IL, USA), which was
eluted with 50 mM glycine, pH 3. Experiments were carried out on an AKTA Prime FPLC system
(GE Healthcare, Chicago, IL, USA). Resulting elution fractions were tested with the above-mentioned
in vitro proteolysis assay, resolved in SDS-PAGE, and stained with Coomassie R250 (Sigma-Aldrich,
St. Louis, MO, USA). Positive fractions were then pooled, and subjected to proteomic analysis for
protease identification.
2.9.2. Protein Identification
The above-mentioned elution fractions were resolved by 12% SDS-PAGE, and the resulting whole
gel lanes were cut into ten portions. An analogous treatment was performed for a mock sample. The
gel slices were triturated, in-gel reduced, S-alkylated with iodoacetamide, and trypsinolyzed [18]. The
gel particles were extracted with 25 mM ammonium bicarbonate/acetonitrile (1:1 v/v), and recovered
peptides were desalted on µZip-TipC18 (Millipore, Burlington, MA, USA) devices, using 50% v/v
acetonitrile, 5% v/v formic acid as an eluent. Peptide mixtures were analyzed by nanoLC-ESI-LIT-MS/MS
with a LTQ XL mass spectrometer (Thermo Fisher Scientific, San Jose, CA, USA) equipped with a
Proxeon nanospray source connected to an Easy-nanoLC (Proxeon, Odense, Denmark) [19]. The
peptides were resolved on an Easy C18 column (10 × 0.075 mm, 3 µm) (Proxeon, Odense, Denmark).
The mobile phases were 0.1% v/v aqueous formic acid and 0.1% v/v formic acid in acetonitrile, running
at 300 nL/min. The gradient parameters have previously been published [7]. The spectra were acquired
in the range m/z 400–2000; the acquisition parameters have previously been reported [7]. The raw data
files from nanoLC-ESI-LIT-MS/MS experiments were searched by the MASCOT search engine (version
2.2, Matrix Science, London, UK) against a non-redundant UniProtKB database containing H. sapiens
protein sequences (2018, 174238). The database searching parameters have already been described [7].
The candidate proteins with at least two assigned peptides with an individual confidence level of 95%
were considered as properly identified. The definitive peptide assignment was always associated with
manual spectra visualization and verification.
2.9.3. Functional Enrichment Analysis
The identified proteins from proteomic analysis were functionally characterized using the
Cytoscape plugin ClueGO querying the KEGG metabolic database (10/12/2019) [20,21]. A two-sided
hypergeometric test (corrected using the Benjamini-Hochberg method to control the false discovery
rate) was applied to find enriched and depleted terms (adjusted p ≤ 0.05). The related terms sharing
similar associated genes were fused to reduce redundancy (minimal number of genes = 4; minimal
percentage = 4.0).
2.10. In Vitro Cleavage Assay with Purified Proteasome
The cleavage reaction assay was performed using 125 ng of purified recombinant proteins and
500 ng of 20S proteasome (Enzo Life Sciences, Farmingdale, NY, USA) in 50 mM Tris-HCl pH 7.5,
25 mM KCl, 10 mM NaCl, 1 mM MgCl2 and 1 mM DTT, at 37 ◦C (final reaction volume 20 µL). After
1 h of incubation, the reaction was blocked with 4× Laemmli sample buffer. The reaction products
were then resolved by SDS-PAGE, and immunoblotted for APE1.
3. Results
3.1. APE1 Is Cleaved at the N-Terminal Region in OCI/AML3 Cells
Previous studies showed that APE1 is targeted by granzymes A and K, which are able to generate
truncated protein products (APE1N∆31-35) that are not capable of repairing damaged DNA, thus leading
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to cellular apoptosis [11,12,22]. We previously reported that a truncated APE1 form can be detected in
OCI-AML3 cells expressing the NPM1c+ mutant [13]. In order to map the cleavage site in APE1 and to
identify the protease(s) responsible for protein cleavage, we performed in vitro proteolysis experiments
using whole cells extracts of OCI-AML3 cells that were incubated with purified FLAG-tagged APE1
recombinant proteins from ad hoc engineered HeLa cells [7,23]. For these assays, we used different
recombinant APE1 protein forms as substrates: (i) wild-type APE1 (APE1WT); (ii) an APE1 mutant
in which residues Lys31, Lys32, Asn33 and Asp34 were mutated to Ala (APE131-34Ala); (iii) an APE1
mutant, in which residues Lys27, Lys31, Lys32 and Lys35 were mutated to Ala (APE1K4pleA), mimicking
constitutive acetylation; (iv) an APE1 truncated form lacking the N-terminal portion of 33 amino
acids (APE1N∆33) (Figure 1). While the proteolysis kinetics of the wild-type protein was very quick,
showing a 50% of cleavage upon 6 min of incubation (Figure lA), amino acid substitutions in mutated
variants significantly interfered with the proteolytic event (Figure 1B–D). The 31-34Ala substitution
slowed-down the kinetics of about 3 min (Figure 1B), while the K4pleA one lowered the kinetics
down to 13 min of incubation, also causing a change in the pattern of proteolysis (Figure 1C). Notably,
APE1N∆33 was completely resistant to proteolysis in the investigated time range (Figure 1D), confirming
that the proteolysis involved the N-terminal region of APE1.Biomolecules 2020, 10, x 6 of 14 
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extracts (10 µg) were incubated for the indicated times, at 37 ◦C, with immunopurified FLAG-tagged
APE1 recombinant proteins expressed in HeLa cells in the wild-type form (APE1WT) (A), the APE131-34Ala
form where residues 31-34 were mutated to Ala (B), the APE1K4pleA form where Lys27, Lys31, Lys32 and
Lys35 were mutated to Ala (C), and the APE1N∆33 form lacking 33 amino acids at protein N-terminus
(D). Reactions were separated onto 12% SDS-PAGE, immunoblotted and analyzed using an antibody
specific for the FLAG-tag. A representative Western blotting analysis shows the cleavage of APE1 at
different times. In the diagrams on the right, the quantification of the densitometric signals of the
non-cleaved form of APE1 (S) and the truncated form (P) is reported. (E) The N-terminal domain of
APE1 is truncated in OCI/AML3 cells. Representative Western blotting analysis on OCI/AML 2 and 3
whole cell extracts (10 µg), showing the N-terminal truncation of APE1 in OCI/AML3 cells. Antibodies
used are indicated on the right-hand side. Tubulin was used as loading control.
Additional experiments demonstrated that the above-mentioned proteolytic events involve the
removal of the N-terminal portion of APE1. Indeed, when whole OCI/AML extracts were analyzed by
Western blotting, full length APE1 was recognized by both an anti-APE1 antibody raised against the
C-terminus part of the protein and an antibody recognizing the first 14 amino acids of APE1 N-terminus.
Conversely, the truncated form was recognized by the first antibody but not by the latter (Figure 1E).
Together with those reported in the previous paragraph on APE1WT, APE131-34Ala, APE1K4pleA and
APE1N∆33proteolysis patterns and kinetics, these data clearly demonstrated that the observed APE1
degradation involved the removal of the N-terminal protein portion, possibly targeting proteolysis in
the segment 31–34.
3.2. Characterization of the Proteolytic Sites for APE1 Cleavage
In order to unveil the cleavage site(s) within APE1 N-terminal region and to obtain enzymatic
parameters for this proteolytic reaction, an internally quenched peptide spanning protein residues
26-36 (DABCYL-26SKTAAKKNDK36E-EDANS), including all acetylable Lys residues (Lys27, Lys31,
Lys32 and Lys35), was synthesized and used as substrate for the APE1-directed protease present in the
OCI-AML3 cell extract.
The hydrolytic events toward the substrate were monitored by real-time measuring of changes
in fluorescence. In this case, a potent enhancement of signal upon cleavage is achieved as result
of the presence of the donor/acceptor pair constituted by EDANS and DABCYL groups [16]. Time
course experiments were performed with different substrate concentrations (1–100 µM) at various
enzyme/substrate ratios, and the reaction was monitored for at least 200 min (Figure S1).
The digestion mixtures were then directly analyzed through LC-ESI-IT-MS experiments (Figure 2),
and resulting signals allowed for the deduction of information on the corresponding reaction products,
and consequently on the hydrolysis sites. In particular, the peptide fragment DABCYL-26SKTAA31K
was primarily detected in this mixture, as deduced by the presence of the signal related to (A2 + 2H)2+
ion at m/z 428.9; consistently, the peak at m/z 880.6 corresponding to MH+ ion of the complementary
peptide 32KNDKE36-EDANS (B2 + H)+ was also identified. A consistent proteolytic cleavage at Lys32
was also observed, based on the identification of the peptide Dabcyl-26SKTAAKK32 showing (A3 + H)+
and (A3 + 2H)2+ ions at m/z 986.7 and 493.8, respectively. In addition, the signal at m/z 1270, which
was associated with the adduct (M + H2O −H)+ ion of the fragment TAAKKNDK36E-EDANS, also
suggested Lys27 as minor potential peptide cleavage site.
Altogether, these data clearly suggested Lys31 and Lys32 as the major cleavage sites in APE1
N-terminal region.
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are in icated (m/z, mass-to-charge ratio).
3.3. Granzymes Are not Involved in APE1 Prote l sis ser ed in OCI/AML3 Cells
Since Granzyme B (GZMB) and A (G reported as able to cleave the N-terminal
region f APE1 [ 1], RT-PCR analysis on R e CI/AML2 and OCI/AML3 cells was
carried out to check the expression of thes proteases in the aforementioned cells. t r rt in
Figure 3A clearly show that neither OCI/AML2 nor OCI/AML3 cells express this form of GZMA and
GZMB, in contrast to Jurkat cells used as a positive control for GZMA expression [24]. In addition,
the reported cleavage of APE131-34Ala and APE1K4pleA (Figure 1B,C) definitively excluded a major
contribution by GZMA, as these mutants are resistant to GZMA degradation [11].
To discriminate between OCI/AML cells and to evaluate if the absence of truncated cytoplasmic
APE1 in extracts of OCI/AML2 cells [13] was due to a differential extent of protease activity in this
line, with respect to OCI/AML3, we performed and compared proteolysis experiments with cells
extracts from OCI/AML2 and OCI/AML3 cell lines. We also used Jurkat cell extracts as positive control
for GZMA expression (Figure 3B). The obtained data clearly indicated that the proteolytic activity
on APE1 was significantly reduced in OCI/AML2 cells, compared to the OCI/AML3 counterparts.
In addition, the absence of any truncated APE1 form using Jurkat cell extracts further supported the
notion that this proteolytic activity is not possibly related to GZMA-mediated degradati n. To further
support the evidence for a GZMA-independent mechanism of proteolysis of APE1, we als used the
HL-60 c ll line that does not express this protease [17]. The data reported in Figure 3B clearly show
that, despite GZMA absence, the proteolytic activity observed on APE1 was apparent, confirming
previous data [22,25]. Altogether, these data supported a model in which NPM1c+ expression is
associated with APE1 N-terminal cleavage in a GZMA-independent manner, which is concurrent to its
cytoplasmic accumulation.
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3.4. The Proteasome Machinery Is Involved in APE1 Cleavage
In order to identify the protease(s) responsible for APE1 proteolysis in the OCI/AML3 cell line, we
first sub-fractionated the cell extracts to limit the proteome size to a specific subcellular compartment.
We separately analyzed the cleavage activity of nuclear and cytoplasmic compartments on APE1WT
(Figure 4A, left). The efficacy of the biochemical procedure of sub-fractionation and isolation of the
nuclear and cytoplasmic proteome was confirmed by the specific enrichment of the two compartment
markers LSD1 (for the nucleus) and tubulin (for the cytoplasm). Testing the resulted extracts for
proteolytic activity on APE1WT, only the cytoplasmic extract exhibited a specific activity that was
inhibited by PMSF treatment, which is a specific inhibitor of serine-like proteases (Figure S2).
For the identification of the protease(s) involved in APE1 truncation, a chromatographic approach
was combined with proteomic analysis. In particular, cytoplasmic extracts of OCI/AML3 cells were
at first sub-fractionated through two subsequent chromatographic steps, a cationic-exchange-based
process (on SP resin) followed by an affinity chromatography-based purification (on a benzamidine
column for serine-like proteases) (Figure 4A, right). In both cases, he eluted fractions were then tested
for prot as activity using he recombinant full-length APE1 protei as substrate (Figure S2). This
strategy allowed a recovery of th protease(s) interes in the flow through of the SP column, and
then in specific fractions of the benzamidine-based chromatography, when the above-mentioned flow
through was loaded on the second purification step. The latter fractions were then subjected to further
proteomic analysis for protein identification (Supplementary Table S1). In order to define whether
particular proteolytic cascades may be involved in the degradation of the APE1 protein, we then
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performed functional enrichment analysis of the proteins here identified, using the Cytoscape plugin
ClueGO (Figure 4B). Data analysis using the KEGG pathway database (http://www.genome.jp/kegg/
pathway.html) highlighted an association with the autophagic flux. In particular, the CTSZ (Cathepsin
Z) and CTSC (Cathepsin C) proteases are involved in the lysosomal pathway [26]. Remarkably,
a significant enrichment (p-adj ≤ 0.05) in proteasomal components was identified in the positive
fractions. In fact, PSMB1, PSMB3, PSMB4, PSMB5, PSMB6, PSMA3, PSMA4 and PSMA5 are some of
the proteasome subunits associated with the proteasome pathway enrichment (see Table S2 for the
complete list of proteins) [27].
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loaded onto a HiTrap SP Sepharose column. The resulting flow-throug , enriched for negative charged
proteins, was loaded on a HiTrap Benzamidine column; serine-proteases retained were then eluted and
each fraction was screened for protease activity. Positive fractions were subjected to proteomic analysis
for protein identification. Representative Western blotting analysis on nuclear and cytoplasmic extracts
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of OCI/AML 2 and 3 cell lines, which shows the cytoplasmic localization of the truncated APE1 form in
OCI/AML3 cells. Tubulin and LSD1 were used as markers of cytoplasmic and nuclear localization,
respectively. (B) Functional annotation of the proteins identified in the activity-based positive fractions
as deriving from proteomic analysis. Functionally enriched terms (Benjamini-Hochberg adjusted
p ≤ 0.05) were identified using the Cytoscape plugin ClueGO, querying the KEGG pathway metabolic
database; results were summarized as bar charts. Bars length represents the percentage of overall
proteins associated with the functional term, which are also present in the examined positive fractions;
the exact number of protein associated with each term is shown on the right of each bar, while the
Benjamini-Hochberg adjusted p-value is shown inside the bars. Each color corresponds to one functional
cluster, with cluster representatives highlighted in bold. See Supplementary Table S2 for detailed
information. (C) Inhibition of the proteasome activity reduces APE1 truncation in OCI/AML3 cells.
Representative Western blotting analysis on OCI/AML3 cells treated with 10 µM of MG132 and 100 nM
of BFA for 4 h. Results showed a reduced protease activity in response to MG132. LC3-I to LC3-II
conversion was used as positive control of autophagy induction. Actin was used as loading control.
The amounts of the APE1 cleaved protein band, normalized to untreated cells, are indicated under each
corresponding lane. (D) APE1 recombinant proteins (APE1WT and APE1K4pleA) were incubated in the
absence or in the presence of the 20S proteasome (20S PR); reaction products were analyzed by 12%
SDS-PAGE and Western blotting. Asterisks indicate cleavage products. APE1N∆33 mutant was loaded
as a control for molecular mass comparison.
In order to investigate the possible involvement of the proteasome in the observed APE1 cleavage,
we treated OCI/AML3 cells with an inhibitor of the proteasomal activity. In particular, we treated
OCI/AML3 cells with 10 µM MG132 for 4 h. To exclude any secondary effects due to MG132 treatment
in a cell context, we performed in vitro proteolysis assay pretreating OCI/AML3 cell extracts with
MG132 (Figure S3). As apparent in Figure 4C and in Figure S3, MG132 treatment highly reduced APE1
cleavage, confirming an involvement of the proteasome machinery in the above-mentioned reactions.
Interestingly, the proteolytic degradation was not ascribable to the autophagic pathway, because the
presence of the autophagy inhibitor bafilomycin A1 (BFA) did not hamper APE1 cleavage. To definitively
demonstrate the involvement of the proteasome in APE1 truncation, we treated purified recombinant
APE1 forms with purified 20S proteasome (Figure 4D). APE1WT and APE1K4pleA recombinant proteins
were incubated with the catalytic subunit of the 20S proteasome (20S PR), and the cleavage activity
was inspected by Western blotting analysis. As shown in Figure 4D, different cleavage products were
observed in the case of APE1WT and APE1K4pleA, further supporting a proteasomal-mediated cleavage
of APE1.
4. Discussion
The pursuit of potential multi-pathway regulators in acute myeloid leukemia has led to the
identification of APE1 as a potential therapeutic target [13,28]. Apart from its crucial role as a
DNA-repair enzyme, APE1 is a multifunctional protein acting as a unique nuclear redox factor [29].
Indeed, several studies have shown that through the control of the DNA binding activity of different
transcription factors (i.e., RAR, NF-kB, p53, AP-1 and STAT3) [30], APE1 regulates downstream
transcriptional programs that are important in leukemia cell biology [31]. Therefore, the blockade
of the APE1 redox function, e.g., with compound APX3330, has been extensively characterized and
represents a promising strategy to alter cell survival and growth of different type of solid tumors and
leukemias (acute lymphoblastic leukemia in particular) [31].
However, as knowledge of APE1 different functions has emerged, it has become clear that
the development of APE1 redox and/or endonuclease inhibitors could not be the only choice for
chemotherapeutical strategies. Recent evidence advocates for a better understanding of dysregulation
of APE1 functions due to the impairment of its protein–protein interactions and PTMs. Although this
represents a relatively neglected area, several studies have shown that different diseases are influenced
by the dysregulation of DNA-repair enzyme protein networks [32]. Similarly, APE1 does not operate
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as an isolated protein, but rather dynamically interacts with a multitude of protein partners that
coordinate and influence its activities [33].
The N-terminal portion of APE1 (35 amino acids) represents the region where the majority of these
interactions [23] and PTMs [34] take place. Among PTMs, APE1 acetylation was highly characterized
in terms of structural assignment and consequent biological outcomes. Specifically, acetylated
residues (Lys27, Lys31, Lys32 and Lys35) are clustered in the protein N-terminus and are involved in
protein–protein interactions [7], APE1 binding to RNAs and DNAs [35], endonuclease activity [5,15,35]
and protein binding to nCaRE sequences [36]. Moreover, these residues are ubiquitinated by several
ubiquitin ligases (e.g., MDM2, UBR3 and Parkin) [8,37,38], which thus control the steady state level
of the protein. Additionally, APE1 enzymatic activities are controlled by interactions involving its
N-terminal region [23]. In this context, Nucleophosmin 1 (NPM1) is the most studied APE1 partner,
and represents a paradigmatic example of how dysregulation of this interaction could be envisioned
as a therapeutic strategy [13,39]. Recently, we have characterized that NPM1 stimulates APE1 BER
activity and, most importantly, AML patients bearing NPMc+ were more responsive to chemotherapy,
due to the consequent APE1 accumulation into the cytoplasm [13]. This impaired relocalization of
APE1 resulted in BER deficiencies and constituted a good prognostic factor for chemotherapy. Notably,
we have demonstrated that there is an accumulation of the APE1 N-terminal truncated form in this
cellular context. This proteolytic processing is a known APE1 modification; however, the exact impact
of this process is not clear at present, and it is not known whether it is exclusive of certain cell types
and/or cellular stress conditions. To date, the protease(s) involved in this process remain elusive,
although a role was preliminary ascribed to granzyme A (GzmA) in T lymphocytes [11].
Accordingly, here we deepened the nature of APE1 cleavage in OCI/AML cells by identifying
responsible proteases. First, the use of different APE1 N-terminal mutants and a synthetic peptide
covering the 26–36 region allowed us to demonstrate that Lys31 and Lys32 are the major cleavage sites
in the APE1 N-terminal region. In particular, the mutant APE1K4pleA, in which the four lysine residues
Lys27, Lys31, Lys32 and Lys35 are mutated to alanine to mimic a constitutive acetylation, appeared to
be associated with a decreased hydrolysis kinetics, compared to wild-type counterpart, thus suggesting
a protective role of acetylation in APE1 proteolysis. Afterwards, we performed a dedicated proteomic
analysis for the identification of proteases responsible for the cleavage in OCI/AML3 cells. To optimize
the identification protocol and limit possible false positive results, we sub-fractioned cell extracts into a
cytoplasmic compartment, where the major APE1-truncated form accumulates, and we performed
two chromatography steps to enhance the recovery of putative proteases. Of note, collected fractions
were tested for protease activity over recombinant APE1 before being subjected to proteomic analysis.
Overall, a large number of proteins were identified in protease assay-positive fractions, which were
further functionally characterized. Among pathways identified as having the highest probability, we
focused on the proteasomal machinery as a potential candidate for further investigations.
Preliminary in vitro analysis preformed in OCI/AML3 cells with MG132, a known inhibitor of the
proteasome, showed a reduced APE1 N-terminal cleavage, thus supporting proteomic results. As far
as we know, this is the first time that the proteasome machinery has been linked to APE1 N-terminal
proteolysis. In addition, exploratory experiments with purified proteins suggested a possible role of the
20S proteasome. Further analyses are undoubtedly needed to elucidate the proteasomal mechanism of
this action. It is known that the 20S proteasome can partially cleave proteins that contain unfolded
regions in an ubiquitin-independent process, leading to the formation of cleaved protein with altered
functionality [40]. The fact that the N-terminal region of APE1 has been characterized as an intrinsically
disordered region [41] reinforces the hypothesis that it can act as an accessible target for the 20S
proteasome activity. Many issues regarding this possible regulation remain to be explored. Specifically,
we need to clarify the contribution of APE1 PTMs and interactors involving the N-terminal region in
protecting/stimulating proteasomal degradation. Furthermore, we need to elucidate if this protein
truncation process depends on particular stimuli and/or pathological conditions, although some
preliminary data suggested that serum starvation could prompt APE1 truncation (data not shown).
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Finally, further studies are needed to understand whether this N-terminal truncated form generates
novel protein species with functional properties distinct from the intact protein. Expanding our
knowledge in this area may pave the way toward a deeper understanding of the APE1 relevance
in cancer biology. Though preliminary, our results represent an interesting opportunity for cancer
medicine, as the use of proteasome inhibitors is now considered and encouraged in therapeutic
interventions, especially in acute leukemia [40,42].
Supplementary Materials: The following are available online at http://www.mdpi.com/2218-273X/10/4/531/s1,
Figure S1: Time-course analysis of hydrolysis of internally-quenched fluorescent APE1 26-36 peptide at different
concentrations; Figure S2: Protease activity tested on purified fractions from benzamidine-based chromatography;
Figure S3: Proteasomal inhibitor MG132 decreases APE1 cleavage; Table S1: Identification details of identified
proteins reported in this study; Table S2: Cytoscape/ClueGO functional annotation of the proteins in the positive
fractions sent to mass spectrometry.
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